Introduction

Nonsteroidal anti-inflammatory drugs (NSAIDs) are frequently administered after orthopedic surgery for their anti-inflammatory, antipyretic, and analgesic capabilities. Their anti-inflammatory effects result from inhibition of prostaglandin (PG) biosynthesis via action on the cyclooxygenase (COX) involved in catabolism of arachidonic acid, which is present in the phospholipid membrane of cells1, 2, 3.

Acetaminophen (paracetamol) is a widely used NSAID for its analgesic and mild anti-inflammatory actions. Although its pharmacologic action has not been attributed to a significant inhibition of peripheral prostanoids, Hinz et al4 recently demonstrated that acetaminophen inhibited COX-2 to a degree comparable to the effect of other NSAIDs and selective COX-2 inhibitors.

Several studies demonstrated that indomethacin, ketorolac, diclofenac, and celecoxib, among other NSAIDs, suppress bone growth, remodeling, and repair5, 6, 7, although the mechanism of this action is not fully understood. Research has focused on the activity of osteoblasts, which play an important role in bone formation and regeneration and are reported to have both bone-forming and immunological functions. We draw attention to: the high expression of antigens involved in antigen presentation in bone tissue sections8, primary cultures, and human osteosarcoma cell line MG-639, 10, 11, 12; the elevated expression of various cytokines13, 14; and their phagocytic capacity of osteoblasts against targets of different size and nature11, 12.

Unlike other NSAIDs, the effect of paracetamol on bone tissue has not yet been investigated, despite its very wide therapeutic utilization, especially as an analgesic. We therefore designed a study to explore its effects on molecular, cellular, and functional parameters of osteoblasts treated with a dose of 5 and/or 25 μmol/L, which are within the therapeutic range15. We selected the human osteosarcoma cell line MG63, which is frequently used as model to study the effect of pharmaceuticals on these osteoblasts12, 16, 17.

Materials and methods

Cell line

We used the human osteosarcoma cell line MG63, purchased from American Type Cultures Collection (ATCC, Manassas, VA).

Drugs

Paracetamol (Sigma Chem Comp, St Louis, MO, USA).

Cell Culture

The human osteosarcoma cell line MG63 was maintained in Dulbecco's modified Eagle medium (DMEM; Invitrogen Gibco Cell Culture Products, Carlsbad, CA) with 100 IU/mL penicillin (Lab Roger SA, Barcelona, Spain), 50 μg/mL gentamicin (Braum Medical SA, Jaen, Spain), 2.5 μg/mL amphotericin B (Sigma, St Louis, MO, USA), 1% glutamine (Sigma, St Louis, MO, USA), 2% HEPES (Sigma, St Louis, MO, USA), and supplemented with 10% fetal bovine serum (FBS) (Gibco, Paisley, UK). Cultures were kept at 37 °C in a humidified atmosphere of 95% air and 5% CO2. Cells were detached from the culture flask with a solution of 0.05% Trypsin (Sigma, St Louis, MO, USA) and 0.02% ethylenediaminetetraacetic acid (EDTA) (Sigma, St Louis, MO, USA) and then washed and suspended in complete culture medium with 10% FBS.

Cell proliferation assay

Osteoblasts were seeded at 1×104 cells/mL per well into a 24-well plate (Falcon, Becton Dickinson Labware, NJ, USA) without FBS and cultured for 24 h with the different concentrations of paracetamol (5–25 μmol/L) at 37 °C. Cells were detached, washed, and suspended in PBS and then immediately analyzed in a flow cytometer Ortho Absolute (Ortho Diagnostic System, Raritan, USA). All experiments included an internal control, ie, cells incubated under the same conditions but without paracetamol.

Antigenic phenotype by flow cytometry

Cultured osteoblastic cells were previously treated with 25 μmol/L of paracetamol in FBS-free medium for 24 h at 37 °C. They were then detached from the culture flask by treatment with 0.4% EDTA solution, washed, and suspended in phosphate-buffered saline (PBS) at 2×104 cells/mL. Cells were labeled by direct staining with the MABs shown in Table 1. Aliquots of 100 μL of the cell suspension were incubated with 10 μL of the appropriate MAB for 30 min at 4 °C in the dark. Cells were washed, suspended in 1 mL PBS, and immediately analyzed in a flow cytometer with argon laser (Facs Vantage Becton Dickinson, Palo Alto, California, USA) at a wavelength of 488 nm to determine fluorescent cell percentage. As controls, untreated cells were stained with the MABs. The percentage of antibody-positive cells was calculated from counts of 2000–3000 cells. At least four experiments were run for each antigen.

Table 1 Monoclonal antibodies (MABs) used to study antigenic phenotype on cultured human osteoblastic-like cells, with their specificity, the fluorochrome used to label the antibody, and the supplier. FITC: Fluorescein-isothiocyanate. PE: Phycoerythrin.

Osteocalcin synthesis

Osteocalcin was quantified in culture supernatants by using the N-tact® osteo SP kit for IRMA osteocalcin (Diasorin-Stillwater, Minesota, USA). For this purpose, cells were cultured for 24 h in FBS-free medium in the presence of 25 μmol/L of paracetamol, and the supernatant was obtained by centrifuge at 1600 r/min. Samples were analyzed in duplicate using the N-tact® osteo SP kit. Results were expressed in picograms of osteocalcin/mL×104 cells. Supernatants of cultures kept under the same conditions but without treatment served as controls.

Phagocytic activity of MG63 lines

Phagocytic activity was studied by flow cytometry. Cultured human MG63 osteosarcoma cells treated with 25 μmol/L of paracetamol and untreated control cells were cultured without FBS and detached from the culture flask by treatment with 0.04% EDTA solution, washed, and then suspended in complete culture medium with 10% FBS at 2×104 cells/mL. Cells were labeled by direct staining with labeled latex beads. One hundred microliters of cell suspension were incubated with 200 μL carboxylated FICT-labeled latex beads of 2 μm diameter (Sigma Adrich, St Louis, USA) for 30 min at 37 °C in darkness. Cells were washed, suspended in 1 mL PBS, and immediately analyzed in a flow cytometer (Fasc Vantage Becton Dickinson, Palo Alto, California, USA). Results were expressed as percentage of cells positive for phagocytosis and mean channel fluorescence, which correlates with the number of particles phagocytosed.

Statistical analysis

Statistical comparisons were determined by using the Student's t-test, and P<0.05 was considered significant.

Results

Effect of paracetamol treatment on proliferation of MG63 cell line

The effects of 24-h treatment with each paracetamol dose (5 or 25 μmol/L) on cell growth of the MG63 cell line were determined by cell count, finding a statistically significant reduction in MG63 cell proliferation with both doses (P<0.01 for both dose). After 24 h culture of 104 cells in each case, the mean viable cell count was 39.53×104 cells/mL in the control cultures versus 28.37×104 cells/mL in the 5 μmol/L-treated cultures and 26.18×104 cells/mL in the 25 μmol/L-treated cultures (Figure 1). Because a greater effect on proliferation was observed with the higher dose (25 μmol/L), it was selected as the dose to be used in analyses of the effects on the remaining study parameters.

Figure 1
figure 1

Effects of acetaminophen on osteoblast proliferation in MG63 cell line after 24 h of incubation at 5 or 25 μmol/L. Data are shown in the mean±SEM. Data from acetaminophen-treated and control cultures were compared using the Student's t-test. cP<0.01.

Effect of paracetamol treatment on antigenic phenotype of MG63 cell line

Using flow cytometry, we studied the effect of treatment with 25 μmol/L paracetamol on the expression of different surface markers of the MG63 cell line in order to determine its antigenic profile. Results obtained showed that treatment with 25 μmol/L of paracetamol for 24 h significantly increased the expression of CD21, CD44, CD80, CD86, and HLA-DR antigens (P<0.01 for CD21, P<0.05 for CD44 and P<0.01 for CD80, CD86, and HLA-DR), but had no effect on CD13 and CD54 antigens (Figure 2, Table 2).

Figure 2
figure 2

Flow cytometry analysis of MG63 cell line after 24 h of incubation. Cultures were treated with 25 μmol/L of acetaminophen (white), and the non-drug treated cultures were the control (black). bP<0.05, cP<0.01.

Table 2 Expression of different antigens in MG63 cell line after 24 h of incubation with 25 μmol/L of acetaminophen by flow cytometry. Data are shown in the mean±SEM. bP<0.05, cP<0.01 vs control.

Effect of paracetamol treatment on osteocalcin synthesis in MG-63 cell line

The effect of paracetamol on cell differentiation/maturation was studied by using osteocalcin synthesis as a marker. According to the osteocalcin levels in culture supernatants, treatment with 25 μmol/L paracetamol for 24 h significantly decreased osteocalcin synthesis (P<0.05), finding mean values of 0.50 pg/mL×104 cells in the treated cultures versus 2.60 pg/mL×104 cells in the untreated (control) cultures (Figure 3).

Figure 3
figure 3

Effects of acetaminophen on quantitative determination of osteocalcin in MG63 cell line after 24 h of incubation with 25 μmol/L of acetaminophen. Data are shown as mean±SEM. cP<0.01.

Effect of paracetamol treatment on phagocytic activity of MG63 line

Table 3 and Figure 4 show the effects of paracetamol on the phagocytic capacity of the MG63 line (analyzed by flow cytometry) which was significantly decreased after a 24-h treatment with 25 μmol/L paracetamol (P<0.01) (Table 3, Figure 4).

Table 3 Effects of acetaminophen on phagocytic capacity in MG-63 cell line after 24 h treatment at 25 μmol/L. Data are expressed as mean±SEM. Comparisons of data between treatment and control culture were evaluated by Student's t-test. Data are shown in the mean±SEM. cP<0.01.
Figure 4
figure 4

Fluorescence histogram of the expression of phagocytic activity of MG63 cell line after treatment with acetaminophen studied by flow cytometry. Cultures were treated with 25 μmol/L of acetaminophen (white), and the non-drug treated cultures were the control (black). Experiments were repeated at least three times. Data are shown in the mean±SEM. cP<0.01.

Discussion

This study showed that 5 and 25 μmol/L paracetamol, within the therapeutic dose range17, may exert a short-term inhibitory effect on the proliferative capacity of MG63 cell line. Bone tissue can regenerate under physiological conditions, but alterations during early wound-healing may delay bone regeneration or, in implants, osseointegration. These results are in agreement with the effects of other NSAIDs on osteoblast growth reported in in vivo and in vitro studies6, 7, 19, 20. For some time, this adverse effect on bone tissue has largely been attributed to the role of PGE2 in bone formation5, 6, 7. However, Chang et al21 showed that NSAIDs significantly arrest the cell cycle in G0/G1 and induce cytotoxicity and osteoblast cell death; they reported that the cytotoxic and apoptotic effects of NSAIDs on osteoblasts might not be prostaglandin-related. Hence, it has been proposed that the induction by NSAIDs of cell cycle arrest and cell death in osteoblasts may be an important mechanism contributing to their suppressive effect on bone formation. Studies on cell lines from other tissues showed that NSAIDs produce cell cycle arrest and induce apoptosis22, 23, 24, 25. However, the underlying mechanism is thought to be complex and various factors have been implicated, including PG synthesis inhibition, apoptosis induction by different pathways, cell cycle alteration or arrest, and the dose of the NSAID in question26, 27, 28.

The present study showed that paracetamol affects osteocalcin synthesis, antigenic profile, and phagocytic activity. Type I collagen, alkaline phosphatase, and osteocalcin can all be used as markers of osteoblast maturation. Osteocalcin was selected for this study because it is the most abundant non-collagenous protein of bone, and its synthesis increases during final stages of osteoblast differentiation and maturation29. Osteocalcin synthesis was lower during cell differentiation, suggesting that this pharmaceutical not only decreases proliferative capacity but may also arrest osteoblast differentiation.

A similar effect on the antigenic profile of paracetamol treatment was previously reported in osteoblasts in inflammatory situations in vitro and in vivo13, 30. This effect is explained as the response of osteoblasts to proinflammatory situations, in which there appears to be an activation of their immune function to the detriment of their bone forming function and their differentiation/maturation. This is supported by our findings of no change in the percentage expression of CD54 molecule and a decrease in osteocalcin synthesis.

Osteoblasts and dendritic cells have characteristics in common, including cytokine synthesis, phagocytic capacity, antigenic presentation to T lymphocytes, and the expression of certain antigens. It has been reported that dendritic cells increase expression of class II and costimulatory molecules in some situations, eg, infections, finding that the expression of chemokine receptors and adhesion molecules was modified in the presence of microbial products31. This effect is usually found in parallel with a decrease in the phagocytic capacity of the cell, interpreted as a process of cell activation aimed at responding to specific situations, with an increase in antigen presentation to T lymphocytes and a reduction in phagocytic capacity. Paracetamol may act in a similar manner, activating the osteoblast and producing an increase in the expression of certain membrane antigens and a decrease in its phagocytic capacity. These results reflect a common situation observed in many cell types, which transform their function under treatment, as reported for macrophages, decidual cells and fibroblasts32, 33, 34, 35.

These experimental data indicate that paracetamol may have an effect on bone tissue, modifying various physiological parameters of osteoblasts. It should be taken account that the MG63 cell line was used as osteoblast model, with the limitations that this implies, although it is one of the most widely used lines in the study of the effect of drugs on osteoblasts12, 16, 17. Further research is warranted to evaluate the use of this drug in patients requiring bone regeneration.

Author contribution

Lourdes DíAZ-RODRíGUEZ: performed research; analyzed data and wrote the paper; Olga GARCíA-MARTíNEZ: performed research; Manuel ARROYO-MORALES: collaboration in development of performed research; BELéN RUBIO-RUIZ: collaboration in development of performed research; CONCEPCIóN RUIZ: designed research, analyzed data, and wrote the paper.